Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Mar;117(5):891–901. doi: 10.1111/j.1476-5381.1996.tb15277.x

Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.

J P van Kats 1, L M Sassen 1, A H Danser 1, M P Polak 1, L K Soei 1, F H Derkx 1, M A Schalekamp 1, P D Verdouw 1
PMCID: PMC1909430  PMID: 8851507

Abstract

1. The role of the renin-angiotensin system in the regulation of myocardial contractility is still debated. In order to investigate whether renin inhibition affects myocardial contractility and whether this action depends on intracardiac rather than circulating angiotensin II, the regional myocardial effects of systemic (i.v.) and intracoronary (i.c.) infusions of the renin inhibitor remikiren, were compared and related to the effects on systemic haemodynamics and circulating angiotensin II in open-chest anaesthetized pigs (25-30 kg). The specificity of the remikiren-induced effects was tested (1) by studying its i.c. effects after administration of the AT1-receptor antagonist L-158,809 and (2) by measuring its effects on contractile force of porcine isolated cardiac trabeculae. 2. Consecutive 10 min i.v. infusions of remikiren were given at 2, 5, 10 and 20 mg min-1. Mean arterial pressure (MAP), cardiac output (CO), heart rate (HR), systemic vascular resistance (SVR), myocardial oxygen consumption (MVO2) and left ventricular (LV) dP/dtmax were not affected by remikiren at 2 and 5 mg min-1, and were lowered at higher doses. At the highest dose, MAP decreased by 48%, CO by 13%, HR by 14%, SVR by 40%, MVO2 by 28% and LV dp/dtmax by 52% (mean values; P < 0.05 for difference from baseline, n = 5). The decrease in MVO2 was accompanied by a decrease in myocardial work (MAP x CO), but the larger decline in work (55% vs. 28%; P < 0.05) implies a reduced myocardial efficiency ((MAP x CO)/MVO2). 3. Consecutive 10 min i.c. infusions of remikiren were given at 0.2, 0.5, 1, 2, 5 and 10 mg min-1. MAP, CO, MVO2 and LV dP/dtmax were not affected by remikiren at 0.2, 0.5 and 1 mg min-1, and were reduced at higher doses. At the highest dose, MAP decreased by 31%, CO by 26%, MVO2 by 46% and LV dP/dtmax by 43% (mean values; P < 0.05 for difference from baseline, n = 6). HR and SVR did not change at any dose. 4. Thirty minutes after a 10 min i.v. infusion of the AT1 receptor antagonist, L-158,809 at 1 mg min-1, consecutive 10 min i.c. infusions (n = 5) of remikiren at 2, 5 and 10 mg min-1 no longer affected CO and MVO2, and decreased LV dP/dtmax by maximally 27% (P < 0.05) and MAP by 14% (P < 0.05), which was less than without AT1-receptor blockade (P < 0.05). HR and SVR remained unaffected. 5. Plasma renin activity and angiotensin I and II were reduced to levels at or below the detection limit at doses of remikiren that were not high enough to affect systemic haemodynamics or regional myocardial function, both after i.v. and i.c. infusion. 6. Remikiren (10(-10) to 10(-4) M) did not affect contractile force of porcine isolated cardiac trabeculae precontracted with noradrenaline. In trabeculae that were not precontracted no decrease in baseline contractility was observed with remikiren in concentrations up to 10(-5) M, whereas at 10(-4) M baseline contractility decreased by 19% (P < 0.05). 7. Results show that with remikiren i.v., at the doses we used, blood pressure was lowered primarily by vasodilation and with remikiren i.c. by cardiac depression. The blood levels of remikiren required for its vasodilator action are lower than the levels affecting cardiac contractile function. A decrease in circulating angiotensin II does not appear to be the sole explanation for these haemodynamic responses. Data support the contention that myocardial contractility is increased by renin-dependent angiotensin II formation in the heart.

Full text

PDF
891

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Admiraal P. J., Derkx F. H., Danser A. H., Pieterman H., Schalekamp M. A. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990 Jan;15(1):44–55. doi: 10.1161/01.hyp.15.1.44. [DOI] [PubMed] [Google Scholar]
  2. Bier J., Sharaf B., Gewirtz H. Origin of anterior interventricular vein blood in domestic swine. Am J Physiol. 1991 May;260(5 Pt 2):H1732–H1736. doi: 10.1152/ajpheart.1991.260.5.H1732. [DOI] [PubMed] [Google Scholar]
  3. Campbell D. J. Circulating and tissue angiotensin systems. J Clin Invest. 1987 Jan;79(1):1–6. doi: 10.1172/JCI112768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chang R. S., Siegl P. K., Clineschmidt B. V., Mantlo N. B., Chakravarty P. K., Greenlee W. J., Patchett A. A., Lotti V. J. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1992 Jul;262(1):133–138. [PubMed] [Google Scholar]
  5. Christe M. E., Perretta A. A., Li P., Capasso J. M., Anversa P., Rodgers R. L. Cilazapril treatment depresses ventricular function in spontaneously hypertensive rats. Am J Physiol. 1994 Nov;267(5 Pt 2):H2050–H2057. doi: 10.1152/ajpheart.1994.267.5.H2050. [DOI] [PubMed] [Google Scholar]
  6. Clozel J. P., Fischli W. Comparative effects of three different potent renin inhibitors in primates. Hypertension. 1993 Jul;22(1):9–17. doi: 10.1161/01.hyp.22.1.9. [DOI] [PubMed] [Google Scholar]
  7. Danser A. H., Koning M. M., Admiraal P. J., Derkx F. H., Verdouw P. D., Schalekamp M. A. Metabolism of angiotensin I by different tissues in the intact animal. Am J Physiol. 1992 Aug;263(2 Pt 2):H418–H428. doi: 10.1152/ajpheart.1992.263.2.H418. [DOI] [PubMed] [Google Scholar]
  8. Danser A. H., Koning M. M., Admiraal P. J., Sassen L. M., Derkx F. H., Verdouw P. D., Schalekamp M. A. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol. 1992 Aug;263(2 Pt 2):H429–H437. doi: 10.1152/ajpheart.1992.263.2.H429. [DOI] [PubMed] [Google Scholar]
  9. Danser A. H., van Kats J. P., Admiraal P. J., Derkx F. H., Lamers J. M., Verdouw P. D., Saxena P. R., Schalekamp M. A. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension. 1994 Jul;24(1):37–48. doi: 10.1161/01.hyp.24.1.37. [DOI] [PubMed] [Google Scholar]
  10. Delabays A., Nussberger J., Porchet M., Waeber B., Hoyos P., Boger R., Glassman H., Kleinert H. D., Luther R., Brunner H. R. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension. 1989 Jun;13(6 Pt 2):941–947. doi: 10.1161/01.hyp.13.6.941. [DOI] [PubMed] [Google Scholar]
  11. Derkx F. H., van den Meiracker A. H., Fischli W., Admiraal P. J., Man in't Veld A. J., van Brummelen P., Schalekamp M. A. Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact. Am J Hypertens. 1991 Jul;4(7 Pt 1):602–609. doi: 10.1093/ajh/4.7.602. [DOI] [PubMed] [Google Scholar]
  12. Duncker D. J., Heiligers J. P., Saxena P. R., Verdouw P. D. Nisoldipine and perfusion of post-stenotic myocardium in conscious pigs with different degrees of concentric stenosis. Br J Pharmacol. 1988 May;94(1):219–227. doi: 10.1111/j.1476-5381.1988.tb11518.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Erdös E. G. Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension. 1990 Oct;16(4):363–370. doi: 10.1161/01.hyp.16.4.363. [DOI] [PubMed] [Google Scholar]
  14. Fischli W., Clozel J. P., Breu V., Buchmann S., Mathews S., Stadler H., Vieira E., Wostl W. Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. Hypertension. 1994 Aug;24(2):163–169. doi: 10.1161/01.hyp.24.2.163. [DOI] [PubMed] [Google Scholar]
  15. Fischli W., Clozel J. P., el Amrani K., Wostl W., Neidhart W., Stadler H., Branca Q. Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension. 1991 Jul;18(1):22–31. doi: 10.1161/01.hyp.18.1.22. [DOI] [PubMed] [Google Scholar]
  16. Fisher N. D., Allan D., Kifor I., Gaboury C. L., Williams G. H., Moore T. J., Hollenberg N. K. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension. 1994 Jan;23(1):44–51. doi: 10.1161/01.hyp.23.1.44. [DOI] [PubMed] [Google Scholar]
  17. Foult J. M., Tavolaro O., Antony I., Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation. 1988 Feb;77(2):337–344. doi: 10.1161/01.cir.77.2.337. [DOI] [PubMed] [Google Scholar]
  18. Gironacci M. M., Adler-Graschinsky E., Peña C., Enero M. A. Effects of angiotensin II and angiotensin-(1-7) on the release of [3H]norepinephrine from rat atria. Hypertension. 1994 Oct;24(4):457–460. doi: 10.1161/01.hyp.24.4.457. [DOI] [PubMed] [Google Scholar]
  19. Hartman J. C., Wall T. M., Hullinger T. G., Shebuski R. J. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993 Jun;21(6):996–1003. doi: 10.1097/00005344-199306000-00022. [DOI] [PubMed] [Google Scholar]
  20. Jeunemaître X., Ménard J., Nussberger J., Guyene T. T., Brunner H. R., Corvol P. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens. 1989 Nov;2(11 Pt 1):819–827. doi: 10.1093/ajh/2.11.819. [DOI] [PubMed] [Google Scholar]
  21. Kiowski W., Beermann J., Rickenbacher P., Haemmerli R., Thomas M., Burkart F., Meinertz T. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation. 1994 Dec;90(6):2748–2756. doi: 10.1161/01.cir.90.6.2748. [DOI] [PubMed] [Google Scholar]
  22. Kleinert H. D. Renin inhibitors: discovery and development. An overview and perspective. Am J Hypertens. 1989 Oct;2(10):800–808. doi: 10.1093/ajh/2.10.800. [DOI] [PubMed] [Google Scholar]
  23. Kleinert H. D., Stein H. H., Boyd S., Fung A. K., Baker W. R., Verburg K. M., Polakowski J. S., Kovar P., Barlow J., Cohen J. Discovery of a well-absorbed, efficacious renin inhibitor, A-74273. Hypertension. 1992 Dec;20(6):768–775. doi: 10.1161/01.hyp.20.6.768. [DOI] [PubMed] [Google Scholar]
  24. Kobayashi M., Furukawa Y., Chiba S. Positive chronotropic and inotropic effects of angiotensin II in the dog heart. Eur J Pharmacol. 1978 Jul 1;50(1):17–25. doi: 10.1016/0014-2999(78)90249-2. [DOI] [PubMed] [Google Scholar]
  25. Lindpaintner K., Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res. 1991 Apr;68(4):905–921. doi: 10.1161/01.res.68.4.905. [DOI] [PubMed] [Google Scholar]
  26. Lindpaintner K., Jin M. W., Niedermaier N., Wilhelm M. J., Ganten D. Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res. 1990 Sep;67(3):564–573. doi: 10.1161/01.res.67.3.564. [DOI] [PubMed] [Google Scholar]
  27. Lindpaintner K., Wilhelm M. J., Jin M., Unger T., Lang R. E., Schoelkens B. A., Ganten D. Tissue renin-angiotensin systems: focus on the heart. J Hypertens Suppl. 1987 Jul;5(2):S33–S38. doi: 10.1097/00004872-198707002-00007. [DOI] [PubMed] [Google Scholar]
  28. Linz W., Schaper J., Wiemer G., Albus U., Schölkens B. A. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992 Dec;107(4):970–975. doi: 10.1111/j.1476-5381.1992.tb13393.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nussberger J., Brunner D. B., Waeber B., Brunner H. R. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension. 1986 Jun;8(6):476–482. doi: 10.1161/01.hyp.8.6.476. [DOI] [PubMed] [Google Scholar]
  30. Poulsen K., Jorgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab. 1974 Nov;39(5):816–825. doi: 10.1210/jcem-39-5-816. [DOI] [PubMed] [Google Scholar]
  31. Raddino R., Pelà G., Poli E., Mascaro F., Manca C., Visioli O. Different effects of captopril and other angiotensin converting enzyme inhibitors on cardiovascular preparations. Pharmacol Res. 1991 Aug;24(2):163–174. doi: 10.1016/1043-6618(91)90031-r. [DOI] [PubMed] [Google Scholar]
  32. Sassen L. M., Duncker D. J., Gho B. C., Diekmann H. W., Verdouw P. D. Haemodynamic profile of the potassium channel activator EMD 52692 in anaesthetized pigs. Br J Pharmacol. 1990 Nov;101(3):605–614. doi: 10.1111/j.1476-5381.1990.tb14128.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sassen L. M., Soei L. K., Koning M. M., Verdouw P. D. The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs. Br J Pharmacol. 1990 Feb;99(2):355–363. doi: 10.1111/j.1476-5381.1990.tb14708.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schaffer L. W., Schorn T. W., Winquist R. J., Strouse J. F., Payne L., Chakravarty P. K., de Laszlo S. E., tenBroeke J., Veber D. F., Greenlee W. J. Acute hypotensive responses to peptide inhibitors of renin in conscious monkeys: an effect on blood pressure independent of plasma renin inhibition. J Hypertens. 1990 Mar;8(3):251–259. [PubMed] [Google Scholar]
  35. Schelling P., Fischer H., Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens. 1991 Jan;9(1):3–15. [PubMed] [Google Scholar]
  36. Siegl P. K., Chang R. S., Mantlo N. B., Chakravarty P. K., Ondeyka D. L., Greenlee W. J., Patchett A. A., Sweet C. S., Lotti V. J. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1992 Jul;262(1):139–144. [PubMed] [Google Scholar]
  37. Tree M., MacArthur K., Inglis G., Leckie B., Lever A. F., Morton J. J., Szelke M. Effects of the renin inhibitor H77 on angiotensin II, arterial pressure and cardiac function in conscious dogs: comparison with captopril. J Hypertens Suppl. 1989 Apr;7(2):S51–S55. doi: 10.1097/00004872-198904002-00012. [DOI] [PubMed] [Google Scholar]
  38. Urata H., Healy B., Stewart R. W., Bumpus F. M., Husain A. Angiotensin II receptors in normal and failing human hearts. J Clin Endocrinol Metab. 1989 Jul;69(1):54–66. doi: 10.1210/jcem-69-1-54. [DOI] [PubMed] [Google Scholar]
  39. Weber M. A., Neutel J. M., Essinger I., Glassman H. N., Boger R. S., Luther R. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation. 1990 Jun;81(6):1768–1774. doi: 10.1161/01.cir.81.6.1768. [DOI] [PubMed] [Google Scholar]
  40. Wessale J. L., Calzadilla S. V., Boyd S. A., Baker W. R., Stein H. H., Kovar P. J., Barlow J., Klinghofer V., Mantei R., Kleinert H. D. Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs. J Cardiovasc Pharmacol. 1993 Oct;22(4):644–652. doi: 10.1097/00005344-199310000-00020. [DOI] [PubMed] [Google Scholar]
  41. Wessale J. L., Kleinert H. D., Calzadilla S. V., Kovar P. J., Rosenberg S. H. Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs. Am J Hypertens. 1993 Jun;6(6 Pt 1):514–521. doi: 10.1093/ajh/6.6.514. [DOI] [PubMed] [Google Scholar]
  42. Wood J. M., Baum H. P., Forgiarini P., Gulati N., Jobber R. A., Neisius D., Hofbauer K. G. Haemodynamic effects of acute and chronic renin inhibition in marmosets. J Hypertens Suppl. 1989 Apr;7(2):S37–S42. doi: 10.1097/00004872-198904002-00009. [DOI] [PubMed] [Google Scholar]
  43. Wood J. M., Mah S. C., Baum H. P., de Gasparo M., Cumin F., Rüeger H., Nussberger J. Evaluation of a potent inhibitor of subprimate and primate renins. J Pharmacol Exp Ther. 1990 May;253(2):513–517. [PubMed] [Google Scholar]
  44. Zusman R. M., Burton J., Christensen D., Nussberger J., Dodds A., Haber E. Hemodynamic effects of a competitive renin inhibitory peptide in humans: evidence for multiple mechanisms of action. Trans Assoc Am Physicians. 1983;96:365–374. [PubMed] [Google Scholar]
  45. de Gasparo M., Cumin F., Nussberger J., Guyenne T. T., Wood J. M., Menard J. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol. 1989 May;27(5):587–596. doi: 10.1111/j.1365-2125.1989.tb03421.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. van den Meiracker A. H., Admiraal P. J., Derkx F. H., Kleinbloesem C., Man in 't Veld A. J., van Brummelen P., Mulder P., Schalekamp M. A. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J Hypertens. 1993 Aug;11(8):831–838. doi: 10.1097/00004872-199308000-00010. [DOI] [PubMed] [Google Scholar]
  47. van den Meiracker A. H., Admiraal P. J., Man in 't Veld A. J., Derkx F. H., Ritsema van Eck H. J., Mulder P., van Brummelen P., Schalekamp M. A. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension. BMJ. 1990 Jul 28;301(6745):205–210. doi: 10.1136/bmj.301.6745.205. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES